U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...

Discover the life-extending approaches to managing heart failure through medication adherence, lifestyle modifications, and ...

Women of childbearing age who had both ovaries removed in a procedure called bilateral oophorectomy were more likely to ...

Alnylam Pharmaceuticals' shares rose more than 10% on Friday after the drugmaker secured U.S. approval for its heart disease drug, setting the stage for the 23-year-old biotech's next phase of growth.

A protocol for transitioning patients with heart failure and a left ventricular assist device to a stepdown unit from the ICU ...

Affecting 1 in 500 people, hypertrophic cardiomyopathy is a condition in which the walls of the left ventricle, the heart's ...

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...

Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old biotech — if it can beat out stiff competition from the likes of Pfizer ...

Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.

Discover how menopause affects heart health through hormonal changes, cholesterol shifts, body fat redistribution, blood ...

Alnylam Pharmaceuticals' shares rose about 7% before the bell on Friday following U.S. approval for its drug for a rare and deadly heart disease, securing an entry into a market dominated by Pfizer's ...

Researchers have shed new light on how a type of heart valve disease -- aortic valve stenosis -- progresses differently in males and females.